JP2006508098A5 - - Google Patents

Download PDF

Info

Publication number
JP2006508098A5
JP2006508098A5 JP2004548931A JP2004548931A JP2006508098A5 JP 2006508098 A5 JP2006508098 A5 JP 2006508098A5 JP 2004548931 A JP2004548931 A JP 2004548931A JP 2004548931 A JP2004548931 A JP 2004548931A JP 2006508098 A5 JP2006508098 A5 JP 2006508098A5
Authority
JP
Japan
Prior art keywords
cancer
compound according
group
hydrogen
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004548931A
Other languages
English (en)
Japanese (ja)
Other versions
JP4847014B2 (ja
JP2006508098A (ja
Filing date
Publication date
Priority claimed from US10/291,863 external-priority patent/US6710075B2/en
Application filed filed Critical
Priority claimed from PCT/AU2003/001463 external-priority patent/WO2004041812A1/en
Publication of JP2006508098A publication Critical patent/JP2006508098A/ja
Publication of JP2006508098A5 publication Critical patent/JP2006508098A5/ja
Application granted granted Critical
Publication of JP4847014B2 publication Critical patent/JP4847014B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004548931A 2002-11-08 2003-11-06 治療化合物および方法 Expired - Fee Related JP4847014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/291,863 US6710075B2 (en) 2000-07-05 2002-11-08 Therapeutic compounds and methods
US10/291,863 2002-11-08
PCT/AU2003/001463 WO2004041812A1 (en) 2002-11-08 2003-11-06 Therapeutic compounds and methods

Publications (3)

Publication Number Publication Date
JP2006508098A JP2006508098A (ja) 2006-03-09
JP2006508098A5 true JP2006508098A5 (https=) 2010-08-26
JP4847014B2 JP4847014B2 (ja) 2011-12-28

Family

ID=32312131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004548931A Expired - Fee Related JP4847014B2 (ja) 2002-11-08 2003-11-06 治療化合物および方法

Country Status (5)

Country Link
EP (1) EP1569928A4 (https=)
JP (1) JP4847014B2 (https=)
AU (1) AU2003277988A1 (https=)
CA (1) CA2504999A1 (https=)
WO (1) WO2004041812A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5249508B2 (ja) 2006-11-06 2013-07-31 三菱重工業株式会社 軌道系交通システム
BR112013032306B1 (pt) 2011-06-16 2021-05-25 Korea Research Institute Of Chemical Technology derivados de indanona, método de preparação dos mesmos, composições farmacêuticas e uso dos mesmos para prevenção ou tratamento de doenças virais
ES2863985T3 (es) 2012-12-14 2021-10-13 Korea Res Inst Chemical Tech Nuevo compuesto, sal farmacéuticamente aceptable o isómero óptico del mismo, método para prepararlo y composición farmacéutica para la prevención o el tratamiento de enfermedades virales que lo contienen como ingrediente activo
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
JP7592748B2 (ja) 2020-04-20 2024-12-02 ノバルティス アーゲー 抗ウイルス1,3-ジ-オキソ-インデン化合物
US12083092B2 (en) 2020-04-20 2024-09-10 Novartis Ag Antiviral 1,3-di-oxo-indene compounds
CN115385924B (zh) * 2022-10-06 2023-10-13 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19835325A1 (de) * 1998-08-05 2000-02-10 Bayer Ag Verwendung von Cyclopentabenzofuran-Derivaten zur Bekämpfung von NF-kB abhängigen Krankheiten
AUPQ866500A0 (en) * 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods

Similar Documents

Publication Publication Date Title
JP4544446B2 (ja) sPLA2阻害作用を有するピロロ[1,2−b]ピリダジン誘導体
EP1610779B1 (en) 3-oxo-1,3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors
CA2917965C (fr) Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004096806A1 (ja) 縮合イミダゾール誘導体
HU229314B1 (en) Polymorphs of an epothilone analog
EP3164393B1 (fr) Dérivés de flavaglines
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
TW200906401A (en) Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
JP2006508098A5 (https=)
FR2917413A1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2014020101A1 (fr) Derives de griseofulvine
EP1773835A2 (fr) Derives de pyrido-pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer
CN119522098A (zh) 用于治疗精神障碍的吡啶衍生物
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
RU2639875C2 (ru) Производное фенила
JP2005531602A5 (https=)
JP3215850B2 (ja) ハロアルコキシ基を含有するピロロ[3,2―c]キノリン誘導体及び薬学的に許容されるその塩
JP2008531713A5 (https=)
CN104945415A (zh) 7H-苯并异噁唑并[7,6-e][1,3]噁嗪类衍生物及应用
JPH0560478B2 (https=)
JPH08225534A (ja) 免疫抑制シクロリグナン誘導体
US20090029975A1 (en) 1,3-benzothiazinone derivative and use thereof
ES2334712T3 (es) Compuestos precursores antiritmicos, procedimientos de sintesis y uso de los mismos.
JP7852604B2 (ja) Abhd6アンタゴニストを含有する医薬組成物
JP2021523187A (ja) リナグリプチンおよびその塩の製造のための中間体およびプロセス